Natalie J. Morgan

Natalie J. Morgan

Partner

An Experienced and Versatile Patent Litigator

Natalie’s practice has always focused on patent litigation and counseling in forums around the country. She has extensive experience taking cases of diverse technologies to trial, including life sciences, pharmaceutical, medical device, biotechnology, software, electronic trading, computing, and cellular and wireless telecommunications.
Experienced Litigating in Multiple Forums and Federal Courts

Natalie has litigated matters around the country in multiple forums including multiple districts of California, District of Delaware, District of New Jersey, Northern District of Illinois, multiple districts of Texas, and the International Trade Commission, and before the USPTO Patent Trial and Appeal Board.
Leading Technology and Life Sciences Clients

Natalie’s clients include Amphastar Pharmaceuticals, Inc., Azurity Pharmaceuticals, Inc., GAIN Capital, Interactive Brokers, NuVasive, Inc., and StoneX Group Inc.

Natalie Morgan focuses her practice primarily on patent litigation, and she has been trial counsel in jury, bench, International Trade Commission, and arbitration trials in patent cases. Her cases have covered diverse technologies, including life sciences, biotechnology, pharmaceuticals in Hatch-Waxman patent litigation, and medical devices, as well as software, graphical user interfaces, electronic trading, cellular and wireless telecommunications, and mechanical products in varied fields.

Natalie has extensive experience in managing patent cases and taking them to trial. She counsels clients on all types of intellectual property issues relating to patents, advising on a host of prelitigation strategy issues, litigation strategy, and alternative dispute resolution options. She is also experienced in negotiating and drafting agreements relating to patents.

Natalie has spoken on litigation-related topics at conferences and webcasts, including on topics including willful infringement issues at the AIPLA (American Intellectual Property Law Association) annual meeting in 2018, and on managing third party IP disputes at the 2020 Innovator's Edge Series Webinar.

Natalie is a member of the firm’s Associate Career Development Committee and is a Litigation Career Development Member for the firm’s litigation associates.

Experience

Natalie is a member of the firm’s Associate Career Development Committee and is a Litigation Career Development Member for the firm’s litigation associates.

Education

J.D., University of San Diego School of LawCum Laude, Order of the Coif
B.A., University of California, San Diego

Honors

Honored among 2024 “Leaders of Influence in Law” by San Diego Business Journal

Admissions

State Bar of California
U.S. District Court for the Central District of California
U.S. District Court for the Northern District of California
U.S. District Court for the Southern District of California
U.S. Court of Appeals for the Federal Circuit
U.S. Patent and Trademark Office

Credentials

Education

J.D., University of San Diego School of LawCum Laude, Order of the Coif
B.A., University of California, San Diego

Honors

Honored among 2024 “Leaders of Influence in Law” by San Diego Business Journal

Admissions

State Bar of California
U.S. District Court for the Central District of California
U.S. District Court for the Northern District of California
U.S. District Court for the Southern District of California
U.S. Court of Appeals for the Federal Circuit
U.S. Patent and Trademark Office

Select Matters

Obtained a favorable jury verdict for client Interactive Brokers in an 11-year battle against Trading Technologies in the Northern District of Illinois. The jury rejected plaintiff’s theory, which sought over $3 billion in damages, instead siding with client Interactive Broker’s theory and limiting damages to $6.6 million. Won summary judgment proving the invalidity of two of the asserted patents prior to trial.
Defended Amphastar Pharmaceuticals, Inc. successfully at trial in the District of Massachusetts against Momenta and Sandoz, proving the asserted patents invalid and unenforceable due to Momenta’s improper conduct before the U.S. Pharmacopeia.
Represented NuVasive, Inc. in a patent infringement litigation against its competitor in the Southern District of California concerning a suite of medical devices that revolutionized spine surgery. Case settled favorably after a successful jury trial. Jury verdict reported as one of top 100 jury verdicts in California in 2022.
Defended Silvergate Pharmaceuticals, Inc.’s patents related to its flagship product in Hatch-Waxman litigation in the District of Delaware. The matter concluded favorably with a settlement.
Represented Azurity Pharmaceuticals and asserted its patents against Amneal in Hatch-Waxman litigation in the District of New Jersey related to Azurity’s Katerzia® product. The matter reached a successful settlement just before trial.
Defended Levita Magnetics International Corp. and its customers in two patent litigations related to Levita’s newly launched surgical system. The matters concluded favorably with a settlement.
Represented Azurity Pharmaceuticals and asserted its patents against Annora in Hatch-Waxman litigation in the District of Delaware related to Azurity’s Epaned® ready-to-use product. The matter reached a successful settlement just before trial.

Matters

Select Matters

Obtained a favorable jury verdict for client Interactive Brokers in an 11-year battle against Trading Technologies in the Northern District of Illinois. The jury rejected plaintiff’s theory, which sought over $3 billion in damages, instead siding with client Interactive Broker’s theory and limiting damages to $6.6 million. Won summary judgment proving the invalidity of two of the asserted patents prior to trial.
Defended Amphastar Pharmaceuticals, Inc. successfully at trial in the District of Massachusetts against Momenta and Sandoz, proving the asserted patents invalid and unenforceable due to Momenta’s improper conduct before the U.S. Pharmacopeia.
Represented NuVasive, Inc. in a patent infringement litigation against its competitor in the Southern District of California concerning a suite of medical devices that revolutionized spine surgery. Case settled favorably after a successful jury trial. Jury verdict reported as one of top 100 jury verdicts in California in 2022.
Defended Silvergate Pharmaceuticals, Inc.’s patents related to its flagship product in Hatch-Waxman litigation in the District of Delaware. The matter concluded favorably with a settlement.
Represented Azurity Pharmaceuticals and asserted its patents against Amneal in Hatch-Waxman litigation in the District of New Jersey related to Azurity’s Katerzia® product. The matter reached a successful settlement just before trial.
Defended Levita Magnetics International Corp. and its customers in two patent litigations related to Levita’s newly launched surgical system. The matters concluded favorably with a settlement.
Represented Azurity Pharmaceuticals and asserted its patents against Annora in Hatch-Waxman litigation in the District of Delaware related to Azurity’s Epaned® ready-to-use product. The matter reached a successful settlement just before trial.

Recent Insights

News Articles

World Intellectual Property Review (WIPR) recognized Wilson Sonsini’s patents practice in the 2025 edition of “WIPR USA Patents,” a comprehensive analysis of the leading law firms and attorneys in the U.S. Wilson Sonsini is ranked as a “Recommended Firm” and is noted for its patent work and for its bench of deeply knowledgeable practitioners. The firm is also recognized for its work in cutting-edge technology sectors, including artificial intelligence and machine learning.

Learn More

Client Highlights

On November 19, 2025, Wilson Sonsini obtained a significant milestone for Azurity Pharmaceuticals, with the Patent Trial and Appeal Board (PTAB) instituting inter partes review in all five petitions the firm filed on Azurity’s behalf. The petitions challenge methods and compositions for treating chemotherapy-induced nausea and vomiting. The Board’s institution decisions found a reasonable likelihood that Azurity will prevail on at least one challenged claim in each proceeding and authorized full trials on the grounds raised. The Board’s decisions are a notable milestone in the current PTAB environment, where institution rates have tightened significantly. Three Administrative Patent Judges independently concluded the challenges were reasonably likely to succeed, and the cases will now proceed to the yearlong trial phase.

Learn More

View All

Recent Events

WSGR Events

Intellectual property is one of the most valued assets of life science companies. As such, founders can be strategic while planning to help minimize the risk of ever reaching the point of entering into an IP dispute. By identifying and managing potential IP disputes from the onset, companies can focus efforts on other growth matters, such as running a thriving business.

Learn More